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现有的研究证实，以整合素 αvβ3 为靶点，RGD 肽为靶向载体，FasL 蛋白为抗








们制备了羟乙基壳聚糖 RGD-FasL 纳米粒 (RF-NPs)，并鉴定其特性、分析其体内外
抑瘤效果，探讨 RGD-FasL 纳米粒在体内外的可能抑瘤机制。 
本实验室构建了 RGD-FasL，采用离子凝胶法制备 RGD-FasL 蛋白羟乙基壳聚糖
缓释纳米粒；通过透射电镜、动态光散射法考察其理化性质；用紫外分光光度仪检测
蛋白浓度来计算其载药率、包封率和体外释放度；通过 MTT 比色法检测对 H22 细
胞增殖活性的影响，流式细胞术检测肝癌 H22 细胞的凋亡率；免疫荧光 Hochest333
42 检测诱导肝癌 H22 细胞的凋亡效果，应用 H22 细胞建立小鼠肝癌模型进行体内
抑瘤研究。Western blotting 检测 Caspase-3、Bcl-2、Bax 蛋白的表达变化来探讨 RF
-NPs 诱导凋亡的可能机制。 















电位为 +25 mV，载药率为 7.75%，包封率为 78.9%，8h 时的释放度为 71.78%，具
有缓释效果。RF-NPs 在 120 mg/L 浓度时对 H22 细胞抑制率为 78.21% ，在 150 




荧光结果发现，与对照组相比 RF-NPs 和 RF 组肿瘤组织阳性细胞计数增加，与 RF
组相比，RF-NPs 组有更好的诱导凋亡的能力；RF-NPs 作用于 H22 肿瘤后所引起的



















The malignant tumor seriously threaten the health of mankind.The commonly used 
cancer therapy methods include surgery, radiotherapy and chemotherapy. However, the 
side effect of radiotherapy and chemotherapy is serious,because normal cells were 
simultaneously killed. Carcinoma of the liver is the common malignant tumor that does 
harm to the human beings’health. liver cancer is the second position lethal factor in all 
tumors, which is next only to lung cancer in city or cancer of the stomach in 
rural.Therefore the research of treating liver cancer is urgent. Now surgical operation, 
chemotherapy, radiotherapy and biotherapy are four kinds of main ways to treat it, In 
recent years,with progress of the pathogenesis and treatment research of liver cancer,it has 
being known that the unusual mechanism of cell apoptosis occurring in liver cancer cells, 
which would be of importance to develop new treatment method.Recently, Immunotherapy 
of biological protein nanoparticles as a new treatment, although in clinical practice also is 
not mature enough, but it is have research prospects for cancer treatment. 
Existing research has confirmed that we fused FasL with the RGD peptide, a ligand of 
αvβ3 integrins, by recombinant DNA technology.We constructed E.coli expression system 
of the fusion protein RGD-FasL (RF).Then we studied its dual activity in vitro, inducing 
tumor cells apoptosis (H22) and the property of tumor targeting.But rapid blood clearance 
and inefficient local expression of functional molecules, in vitro degradation and sustained 
release. Therefore need to find a good protein carrier to protect and improve the effect of 
drugs. Modern nanotechnology as an effective drug delivery systems, able to pass small 
molecules and biological macromolecules therapydrug, the chitosan bran and its 
derivatives in recent years become the focus of the study of nanoparticles loaded with 
protein, it has a specific structure , physical and chemical properties, making it very good 
biocompatibility, biodegradability characteristics, low immunogenicity and biological 
activity, was used as a carrier of chemical drugs, antibodies, proteins, peptides, and genetic 
drugs. To further study the function of the RGD-FasL to improve protein drug effects, we 















in vitro and in vivo antitumor effect, to explore its the possibility of tumor inhibition 
mechanism in vitro and in vivo. 
Our laboratory had constructed RGD-FasL protein, RGD-FasL glycol chitosan based 
nanoparticles were prepared by ionic gelation method ; The physic-chemical properties 
were determined by the ways of TEM and DLS, We examined the release behaviour in 
vitro ,the encapsulation efficiency and loading rate of RF-NPs by ultraviolet 
spectrophotometer,H22 cell proliferative activity was examined by MTT,anticancer effect 
of the H22 hepatoma model established in mice were evaluated. we cultured the rate of 
apoptosis of hepatoma H22 cells induced by RF-NPs and detected by flow cytometry; the 
detection of RF-NPs induced apoptosis effect of H22 cells by immune fluorescence 
Hochest33342 ,Western blotting detection of the protein caspase-3 ,Bcl-2, Bax expression 
in vivo induction apoptosis mechanisms. 
The obtained RF-NPs were approximately spherical in shape with average particle 
size of 198. 3 nm, Zeta potentials of + 25 mV. The entrapment efficiency and loading rate  
was 78.9% and 7.79% respectively, and Release rate after 8h is 71.78%. Also RF-NPs 
showed obvious tumor inhibiting effect, manifested sustained-release of RF in vitro.When 
RF-NPs concentration came to 120 mg/L , its H22 tumor inhibitory rate can be 78.31% in 
vivo by MTT. When Blank NPs concentration came to 150 mg/L , its H22 tumor inhibitory 
rate can be 5.59% by FCM. Hepatotoxicity was detected by HE staining of organs of 
different treated H22-bearing mice. Both of them could demonstrate cell hypotoxicity of 
nanoparticles. Compared with control groups, both RF-NPs and RF groups manifested 
nuclear shrinkage and could induce apoptosis by immune fluorescent Hochest 33342 
staining. Also both RF-NPs and RF experimental groups manifested more positive cells 
number, RF-NPs have better induction of apoptosis in TUNEL staining. Additionally, It 
showed that RF-NPs effect on H22 turmor was closely related to the Caspase-3, Bcl-2，
BAX expression by Western blotting experiment. 
In short , RF-NPs prepared by ionic gelation method included mild preparing 
conditions and simple method, has the potential to make cancer therapy in vivo achievable. 
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每年大约有 50 万人确诊为患有原发性肝癌。在欧洲和美国地区 10 万人口




原发性肝癌是临床上 常见的恶性肿瘤之一，根据 2012 年 新文献报





肝癌标化发病率男性为 35.2 /10 万，女性为 13.3 /10 万。其他高发国家有
韩国(男性为 48.8 /10 万，女性为 11.6 /10 万)等。南北美、北欧和大洋洲
是发病率较低的地区, 如加拿大( 男性为 3.2 /10 万，女性为 1.1 /10 万)等。



























1.1  肝癌的发病病因与治疗手段 







与肝癌有密切关系。肝癌病例 HBsAg 阳性率可高达 81.82%，据报道，在 HBV
阳性的肝癌患者中可见 HBV 基因整合到肝癌细胞 DNA 中，所以将 HBV 视为
肝癌发病的重要因素。全世界 HBV 病毒携带者约为 3 亿，其中约 1.2 亿在中
国，中国是乙型病毒性肝炎高发区，HBV 病毒感染是中国肝癌发生 主要的因
素。罗瑞虹等[3]对中国人群 HBV 感染与原发性肝癌关系病例对照研究分析显示 
HBV 感染与肝癌呈高度关联。涂燕云等[4]对多例肝癌患者进行分析,发现有 HBV 
感染者达 75.1%。HBV 感染者患肝癌的相对危险性为 HCV 感染者的 4 倍，HBV
与 HCV 有联合效应，合并感染者其相对危险性高于两者的单独相对危险性。丁
保国等[5]探讨肝炎病毒感染与 PHC 的关系时发现：HCV、HBV 联合感染，其
发生 PHC 的危险度更加升高。HCV 感染发展为肝硬化增加肝癌的危险性，国外
学者推测 HCV 感染 30 年后有 1%-3% 的感染者将发展为肝癌；HCV 感染 















1%-4% 的感染者发展为肝癌[6]。在我国 HCV 引起的肝癌正引起关注， HBV 和 
HCV 重叠感染对肝癌具有联合效应也得到了不少报道，而单独 HCV 感染却对
肝癌作用不是很明显。许青霞等[7]对肝癌患者、其他肿瘤患者、健康人群中进行 
HCV 感染情况分析。发现肝癌组 HCV 和 HBV 混合感染明显高于其他肿瘤组和



















有可以增强 HBV、亚硝胺、AFT、诱发 HCC 的作用，其促进癌症发生的机制未
明。一些报道认为，乙醇能影响维生素 A 的代谢以及影响细胞色素 P450 活性，
从而加速致癌原的生物转化作用。酒精中毒可致酒精性脂肪肝、酒精性肝炎、酒
精性肝硬化。在酒精性肝炎或肝硬变时，可增加肝细胞癌变的发生。李岩等[8]


















鼠皮下植入 15mg 己烯雌酚小丸，几个月内发生 HCC，如同时投予雌激素拮抗
剂他莫昔芬(三苯氧胺)，则完全可预防 HCC 的发生，表明雌激素参与 HCC 的发
生。在美国，口服避孕药其雌激素含量比我国高出 8 倍，它可引起良性肝腺瘤，
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